icone plus
Contact Abonnez-vous aux actualités
Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
no clinical added value
EYLEA does not provide any improvement in actual benefit (level V, non-existent) compared with LUCENTIS for adults in the treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO).
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
D1ZRZEk4X7FWL8CG
Listen
